Lv1
40 积分 2022-09-22 加入
Type 2 diabetes
20天前
已完结
胰高糖素样肽-1受体激动剂联合胰岛素治疗2型糖尿病专家共识（2025版）
1个月前
已完结
IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective
2个月前
已完结
MASLD, MASH, and the CKM Spectrum: A Roadmap for Multiorgan Clinical Trial Design
2个月前
已完结
MASLD, MASH, and the CKM Spectrum
2个月前
已关闭
Changes in insulin utilization in China from 2020 to 2022
4个月前
已完结
The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
5个月前
已完结
Real-World Multicenter Registry to Determine Management and Quality of Care of Patients with Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases in China (iCaReMe China)
6个月前
已完结
Changes in insulin utilization in China from 2020 to 2022
6个月前
已完结
IcoSema and the evolution of fixed-ratio insulin–GLP-1 receptor agonist therapies
6个月前
已完结
皖公网安备34019202002308
